KRAS and neoplasm: The observed correlation between cytotoxic CD8+ T‐cell tumor infiltrate and KRAS mutation in clinical samples does not necessarily indicate mutant KRAS was a causative factor in reducing tumor‐infiltrating cytotoxic CD8+ T‐cells.